Altamira Therapeutics Ltd.

CYTONASDAQHealthcare

$0.30

+$0.30(+100.00%)

Market Cap$1133556

P/E Ratio—

52W High$0.4158

52W Low$0.3

Avg Volume244K

Open$0.30

Beta2.44

Revenue Financials Earnings

Altamira Therapeutics Ltd. (CYTO) Revenue

Annual & quarterly revenue history · segment & region breakdown

CYTO · revenue · updated Jun 9, 2026

Core revenue metrics

Trailing 12 months

Altamira Therapeutics Ltd. trailing twelve-month (TTM) revenue is $0.00B, a decrease of 100.00% year-over-year from $0.00B in FY2023.

TTM revenue

$0.00B

4-quarter sum · USD

YoY growth

-100.00%

vs FY2023 $0.00B

Price / sales

9.42×

mktCap ÷ TTM rev

Revenue per day

$0M

Est. TTM ÷ 365

Revenue / employee

$12K

10 employees

FY2023

$0.00B

FY2022

$0.00B

5Y CAGR

—

Fiscal year end

Dec 31

Currency

CHF · GAAP

Filing

10-K / 10-Q

Source: FMP · Altamira Therapeutics Ltd. SEC filings · GAAPUpdated: 2026-06-09

Revenue trend

2023 – 2012 · Annual

YoY revenue growth %

revenue trend · revenue chart · revenue by year · revenue history

Revenue history

Fiscal year end	Revenue	Change	Growth
2023-12-31	$0.00B	-$0.00B	-100.00%
2022-12-31	$0.00B	+$0.00B	+378.41%
2021-12-31	$0.00B	-$0.00B	-63.39%
2020-12-31	$0.00B	+$0.00B	—
2019-12-31	$-0.00B	-$0.00B	-104.42%
2018-12-31	$0.00B	+$0.00B	+293.17%
2017-12-31	$0.00B	+$0.00B	—
2016-12-31	$0.00B	+$0.00B	—
2015-12-31	$-0.00B	-$0.00B	—
2014-12-31	$0.00B	+$0.00B	—

CYTO revenue by year · CYTO revenue history · CYTO annual revenue data

About Revenue & Reporting

Revenue (also called sales, net sales, or turnover) is the total income Altamira Therapeutics Ltd. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.

Altamira Therapeutics Ltd. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in CHF.

Data sourced from Altamira Therapeutics Ltd.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.

Figures tie to SEC 10-K/10-Q and FMP income-statement endpoints where noted.

Price history Financial statements Forecast

Frequently asked questions

CYTO revenue · 4 questions

CYTO's trailing twelve-month (TTM) revenue is $0.00B. That is a decrease of 100.00% year-over-year from $0.00B in FY2023.

CYTO revenueCYTO annual revenuewhat is CYTO revenueCYTO TTM revenue

▸ Source: FMP · Altamira Therapeutics Ltd. SEC filings · GAAP · Altamira Therapeutics Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026